{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T10:17:09Z","timestamp":1772360229576,"version":"3.50.1"},"reference-count":31,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2015,10,7]],"date-time":"2015-10-07T00:00:00Z","timestamp":1444176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2010\/02774-5"],"award-info":[{"award-number":["2010\/02774-5"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Thrombosis is the main outcome of many cardiovascular diseases. Current treatments to prevent thrombotic events involve the long-term use of antiplatelet drugs. However, this therapy has several limitations, thereby justifying the development of new drugs. A series of N-oxide derivatives (furoxan and benzofuroxan) were synthesized and characterized as potential antiplatelet\/antithrombotic compounds. All compounds (3a,b, 4a,b, 8a,b, 9a,b, 13a,b and 14a,b) inhibited platelet aggregation induced by adenosine-5-diphosphate, collagen, and arachidonic acid. All compounds protected mice from pulmonary thromboembolism induced by a mixture of collagen and epinephrine; however, benzofuroxan derivatives (13a,b and 14a,b) were the most active compounds, reducing thromboembolic events by up to 80%. N-oxide derivative 14a did not induce genotoxicity in vivo. In conclusion, 14a has emerged as a new antiplatelet\/antithrombotic prototype useful for the prevention of atherothrombotic events.<\/jats:p>","DOI":"10.3390\/molecules201018185","type":"journal-article","created":{"date-parts":[[2015,10,7]],"date-time":"2015-10-07T10:39:13Z","timestamp":1444214353000},"page":"18185-18200","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Synthesis and Preliminary Evaluation of N-Oxide Derivatives for the Prevention of Atherothrombotic Events"],"prefix":"10.3390","volume":"20","author":[{"given":"Leandro","family":"Rosseto","sequence":"first","affiliation":[{"name":"Faculdade de Ci\u00eancias Farmac\u00eauticas, Universidade Estadual Paulista, UNESP, Rodovia Araraquara Ja\u00fa Km 01, 14801-902, Araraquara, SP, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Pires","sequence":"additional","affiliation":[{"name":"Departmento de Farmacologia, Faculdade de Ci\u00eancias M\u00e9dicas, Universidade Estadual de Campinas, UNICAMP, Rua Tess\u00e1lia Vieira de Camargon.126, 13083-887, Campinas, SP, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aylime","family":"Melchior","sequence":"additional","affiliation":[{"name":"Faculdade de Ci\u00eancias Farmac\u00eauticas, Universidade Estadual Paulista, UNESP, Rodovia Araraquara Ja\u00fa Km 01, 14801-902, Araraquara, SP, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priscila","family":"Bosquesi","sequence":"additional","affiliation":[{"name":"Faculdade de Ci\u00eancias Farmac\u00eauticas, Universidade Estadual Paulista, UNESP, Rodovia Araraquara Ja\u00fa Km 01, 14801-902, Araraquara, SP, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aline","family":"Pavan","sequence":"additional","affiliation":[{"name":"Faculdade de Ci\u00eancias Farmac\u00eauticas, Universidade Estadual Paulista, UNESP, Rodovia Araraquara Ja\u00fa Km 01, 14801-902, Araraquara, SP, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sisi","family":"Marcondes","sequence":"additional","affiliation":[{"name":"Departmento de Farmacologia, Faculdade de Ci\u00eancias M\u00e9dicas, Universidade Estadual de Campinas, UNICAMP, Rua Tess\u00e1lia Vieira de Camargon.126, 13083-887, Campinas, SP, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Man","family":"Chung","sequence":"additional","affiliation":[{"name":"Faculdade de Ci\u00eancias Farmac\u00eauticas, Universidade Estadual Paulista, UNESP, Rodovia Araraquara Ja\u00fa Km 01, 14801-902, Araraquara, SP, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Santos","sequence":"additional","affiliation":[{"name":"Faculdade de Ci\u00eancias Farmac\u00eauticas, Universidade Estadual Paulista, UNESP, Rodovia Araraquara Ja\u00fa Km 01, 14801-902, Araraquara, SP, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2015,10,7]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (WHO) Available online: http:\/\/www.who.int\/mediacentre\/factsheets\/fs317\/en\/."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nrd2851","article-title":"The anticoagulants market","volume":"8","author":"Melnikova","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/nrd4365","article-title":"Antithrombotic drugs market","volume":"13","author":"Chaudhari","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1136\/heartjnl-2013-305399","article-title":"Antiplatelet therapy for secondary prevention of coronary artery disease","volume":"100","author":"Pilgrim","year":"2014","journal-title":"Heart"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/FJC.0b013e31818eee5f","article-title":"Aspirin resistance: Focus on clinical endpoints","volume":"52","author":"Pusch","year":"2008","journal-title":"Cardiovasc. Pharmacol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1007\/s11095-010-0209-4","article-title":"Old and new molecular mechanisms associated with platelet resistance to antithrombotics","volume":"27","author":"Tamargo","year":"2010","journal-title":"Pharm. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/nrd2957","article-title":"Antiplatelet therapies for the treatment of cardiovascular disease","volume":"9","author":"Michelson","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.jacc.2005.01.034","article-title":"Resistance to clopidogrel: A review of the evidence","volume":"45","author":"Nguyen","year":"2005","journal-title":"Am. Coll. Cardiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S0140-6736(06)68040-9","article-title":"Aspirin resistance","volume":"367","author":"Hankey","year":"2006","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/sj.bjp.0703156","article-title":"Vasorelaxant and antiplatelet activity of 4,7-dimethyl-1,2,5-oxadiazolo[3,4-d]pyridazine 1,5,6-trioxide: Role of soluble guanylate cyclase, nitric oxide and thiols","volume":"129","author":"Kots","year":"2000","journal-title":"Br. J. Pharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/sj.bjp.0706743","article-title":"Mechanism of action of novel NO-releasing furoxan derivatives of aspirin in human platelets","volume":"148","author":"Turnbull","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"ref_12","unstructured":"Sankaranarayanan, A. (2001). Benzofuroxan Derivatives, Their Therapeutic Uses and Pharmaceutical Compositions. (6,232,331), U.S. Patent."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4837","DOI":"10.1128\/AAC.00052-14","article-title":"Leishmanicidal activities of novel synthetic furoxan and benzofuroxan derivatives","volume":"58","author":"Dutra","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_14","first-page":"758","article-title":"Synthesis and biological evaluation of 1,2,5-oxadiazole N-oxide derivatives as hypoxia-selective cytotoxins","volume":"53","author":"Monge","year":"1998","journal-title":"Pharmazie"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.3390\/molecules19022089","article-title":"Antiplatelet and antithrombotic activities of non-steroidal anti-inflammatory drugs containing an N-acyl hydrazone subunit","volume":"19","author":"Chelucci","year":"2014","journal-title":"Molecules"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1113\/jphysiol.1963.sp007185","article-title":"The aggregation of blood platelets","volume":"168","author":"Born","year":"1963","journal-title":"J. Physiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"5811","DOI":"10.1021\/jm200531f","article-title":"Design, synthesis, and pharmacological evaluation of novel hybrid compounds to treat sickle cell disease symptoms","volume":"54","author":"Lanaro","year":"2011","journal-title":"J. Med. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0022-3565(25)33551-2","article-title":"Mouse antithrombotic assay: A simple method for the evaluation of antithrombotic agents in vivo. Potentiation of antithrombotic activity by ethyl alcohol","volume":"225","author":"DiMinno","year":"1983","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.ejmech.2007.03.032","article-title":"Synthesis and anti-platelet activity of novel arylsulfonate\u2014acylhydrazone derivatives, designed as antithrombotic candidates","volume":"43","author":"Lima","year":"2008","journal-title":"Eur. J. Med. Chem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1016\/j.bmc.2012.01.034","article-title":"Discovery of new orally effective analgesic and anti-inflammatory hybrid furoxanyl N-acylhydrazone derivatives","volume":"20","author":"Cabrera","year":"2012","journal-title":"Bioorg. Med. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1126\/science.280.5367.1268","article-title":"Aspirin-like molecules that covalently inactivate cyclooxygenase-2","volume":"280","author":"Kalgutkar","year":"1998","journal-title":"Science"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1021\/acs.jmedchem.5b00104","article-title":"pkCSM: Predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures","volume":"58","author":"Pires","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.mrgentox.2006.08.010","article-title":"In vivo erythrocyte micronucleus assay. III. Validation and regulatory acceptance of automated scoring and the use of rat peripheral blood reticulocytes, with discussion of non-hematopoietic target cells and a single dose-level limit test","volume":"627","author":"Hayashi","year":"2007","journal-title":"Mutat. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.toxlet.2009.07.006","article-title":"Cytotoxic, mutagenic and genotoxic effects of new anti-T. cruzi 5-phenylethenylbenzofuroxans. Contribution of phase I metabolites on the mutagenicity induction","volume":"190","author":"Cabrera","year":"2009","journal-title":"Toxicol. Lett."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.2174\/1568026614666140506123235","article-title":"Mutagenicity of N-oxide containing heterocycles and related compounds: experimental and theoretical studies","volume":"14","author":"Gabay","year":"2014","journal-title":"Curr. Top Med. Chem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"7583","DOI":"10.1021\/jm300602n","article-title":"Design, synthesis, and pharmacological evaluation of novel hybrid compounds to treat sickle cell disease symptoms. Part II: Furoxan derivatives","volume":"55","author":"Lanaro","year":"2012","journal-title":"J. Med. Chem."},{"key":"ref_28","unstructured":"(2012). Maestro, Schrodinger. version 9.1; Software for docking studies."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1073\/pnas.0909765106","article-title":"Coxibs interfere with the action of aspirin by binding tightly to one monomer of cyclooxygenase-1","volume":"107","author":"Rimon","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_30","unstructured":"(2012). LigPrep, Schrodinger. version 2.5; Software for molecular energy minimization."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/jm0306430","article-title":"Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy","volume":"47","author":"Friesner","year":"2004","journal-title":"J. Med. Chem."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/20\/10\/18185\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T20:49:43Z","timestamp":1760215783000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/20\/10\/18185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,7]]},"references-count":31,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2015,10]]}},"alternative-id":["molecules201018185"],"URL":"https:\/\/doi.org\/10.3390\/molecules201018185","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,7]]}}}